基本情况

刘新泳，博士，山东大学特聘教授，博士生导师；山东省泰山学者特聘专家，浙江钱江特聘专家，山东省医学领军人才, 教育部宝钢优秀教师，享受国务院政府特殊津贴。2014-2026年连续12年入Elsevier药理与毒理学研究领域“中国高引学者”, 连续入选World’s Top 2% Scientists-终身科学影响力榜单; 入选全球顶尖前10万科学家榜单。连续入选化学领域最佳科学家（Ranked  Best Scientists in the field of Chemistry）。

研究领域

基于靶点的抗病毒药物的合理设计、合成与活性研究；基于表型筛选的尿酸转移蛋白结构的抗痛风药物的研究与开发；基于活性天然产物的结构修饰与心脑血管药理活性的研究。

教育及工作经历

1980年考入山东医学院药学系，1984.7年毕业，获得学士学位，同年留校任教（1985.7助教）。

1988.8年考入山东医科大学药物化学专业研究生，1991.7年毕业，获理学硕士学位。同年留校任教。

1992.8年晋升讲师，1994.12年破格晋升为副教授、硕士导师。

1997年3月—1999年3月，02年4-9月两度赴西班牙国家科学院药物研究所，作为访问教授从事国际合作课题研究。

2001.9年晋升教授。

2001.8年考入山东大学药物化学专业博士生，2004.6年获博士学位。

2004年山东大学校聘关键岗教授，2009年山东大学校聘二级岗教授，2018年至今任山东大学特聘教授。

科研项目

1.新型高效抗耐药性核苷（酸）类SARS-CoV-2聚合酶抑制剂的设计、合成与活性评价。国家重点研发计划-国际战略合作，2024.01-2026.12，课题主持人。

2.基于靶标结构的哌嗪类SARS-CoV-2主蛋白酶抑制剂的设计、合成与活性评价。国家自然基金，2024.1-2026.12，课题主持人。

3.建设医药科技成果转移转化公共服务平台项目，中华人民共和国工业和信息化部，2022.01.01-2024.12.31，课题主持人。

4.广谱抗耐药性抗冠状病毒药物研发，山东省自然科学基金重大基础研究项目。2022.1-2024.12，课题主持人。

论文发表

1. Shaoqing Du, Xueping Hu, Ping Li, Shujing Xu, Meehyein Kim*, Xinyong Liu*, Peng Zhan*. Antiviral drug discovery and development: challenges and future directions. Signal Transduct Target Ther, 2026;11(1),69.

2. Jinyuan Wu, Sining Tao, An-Chao Ge, Zhongxia Zhou*, Dongwei Kang*, Xinyong Liu*. Research Progress on the Structural Biology of Paramyxovirus Polymerase and Its Inhibitors. Journal of Medicinal Chemistry, 2026;69(4),3731-3761.

3. Zhenqian Wang, Xiaoyu Shi, Zitao Guo, Zhenkun Wu, Yuexin Xu, Mingyu Yang, Mei Wang, Qian Yang, Ting Wu, Jianxin Pang*, Fan Yi*, Peng Zhan*, Xinyong Liu*. A Novel Pyrrole Acylsulfonamide, Compound 42, as a Dual URAT1/GLUT9 Inhibitor: Potent Urate-Lowering Efficacy, Reduced Off-Target Effects, and Promising Druggability for Hyperuricemia. Journal of Medicinal Chemistry, 2026; 69(9), 10764–10787.

4. Xiaoyu Shi, Cheng Shi, Mingyu Yang, Zeqi Yu, Qian Yang, Zhenming Liu*, Jianxin Pang*, Peng Zhan*, Xinyong Liu*, Tong Zhao*. Pyridoimidazolyl Sulfonamide Compound 2: A Superior Dual-Acting Drug Candidate with Potent URAT1 Inhibition and Anti-Inflammatory Activity for Gout Management. Journal of Medicinal Chemistry, 2026; 69(11), 13099–13120.

5. Qian Yang, Danhui Qi, Wenjie Ye, Xiaoyu Shi, Mingyu Yang, Ting Wu, Zhenkun Wu, Yuexin Xu, Youzhao Wang, Shujing Xu, Zhenqian Wang, Shenghua Gao*, Fan Yi*, Jianxin Pang*, Xinyong Liu*, Peng Zhan*. Discovery of a Novel Thienopyrimidine Derivative as a Potent Dual URAT1/GLUT9 Inhibitor with Enhanced Urate-Lowering Efficacy, Superior Pharmacokinetics, and Favorable Safety Profile for Gout and Hyperuricemia. Journal of Medicinal Chemistry, 2026; 69(10), 11752–11775.

6. Shuo Wang, Feiyue Ma, Craig W Lindsley*, Shujing Xu*, Xinyong Liu*, Peng Zhan*. Recent Advances in Long-Acting Antiviral Agents: Innovations in Design and Strategies for Extended Duration. Journal of Medicinal Chemistry, 2026;69(1),10-29.

7. Zhenzhen Zhou, Yanying Sun, Da Feng, Zhao Wang, Fabao Zhao, Shenghua Gao, Peng Zhan*, Dongwei Kang*, Xinyong Liu*. Structural biology of HIV-1 reverse transcriptase allosteric inhibitors for drug design. Acta Pharmaceutica Sinica B, 2026;16(1),93-121.

8. Sining Tao, Zhenzhen Zhou, Xin Li, Xian-Wei Wang*, Xinyong Liu*, Dongwei Kang*. Recent Advances of Non-Nucleoside Polymerase Inhibitors With Broad-Spectrum Antiviral Activities. Medicinal Research Reviews, 2026;46(4),945-965.

9. Letian Song, Bing Ye, Baohu Li, Leentje Persoons, Dirk Jochmans, Johan Neyts, Steven De Jonghe, Shenghua Gao*, Peng Zhan*, Xinyong Liu*, Discovery of orally bioavailable N-acylated remdesivir derivatives with potent broad-spectrum antiviral activity. Bioorganic chemistry, 2026;175,109758.

10. Hao Lin, Zhongxia Zhou, Lin Zheng, Ying Liu, Da Feng, Xiangyi Jiang 1, Yanying Sun, Xiangkai Ji, Erik De Clercq, Christophe Pannecouque, Chin-Ho Chen, Dongwei Kang, Peng Zhan, Xinyong Liu, Discovery of novel diarylpyrimidine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors: Design, synthesis and biological activity evaluation. Bioorganic chemistry, 2026; 170, 109456.

11. Zhijiao Zhang, Xiaoyu Shi, Ting Wu, Zhuhan He, Ruipeng Liang, Wenjie Ye, Zhenkun Wu, Hui Liao, Fengxin Zheng, Qian Yang, Tong Zhao, Javier Egea, Xinyong Liu*, Jianxin Pang*, Fan Yi*, Peng Zhan*. Discovery of multi-target anti-gout agents from Eurycoma longifolia Jack through phenotypic screening and structural optimization. Nature Communications, 2025;16(1),7430

12. Zhao Wang, Shawn Rumrill, Dongwei Kang, Samuel Desta Guma, Da Feng, Erik De Clercq, Christophe Pannecouque, Chin Ho Chen*, Eddy Arnold*, Francesc Xavier Ruiz*, Xinyong Liu*, Peng Zhan*. Development of enhanced HIV-1 non-nucleoside reverse transcriptase inhibitors with improved resistance and pharmacokinetic profiles. Science Advances. 2025;11(22),eadt8916

13. Sabina Andreu, Kai Tang, Jiahui Zhou, Gabriel Pino-Peco, Nerea López-Carrobles, Raquel Bello-Morales, Daniel Galdo-Torres, Lina Zhang, Federico Gago, José Antonio López-Guerrero*, Xinyong Liu*, Peng Zhan*, Luis Menéndez-Arias*. Discovery of a Baloxavir-Inspired Endonuclease Inhibitor That Prevents Herpes Simplex Virus 1 Replication in Cell Culture and In Vivo. Advanced Science, 2025;12(42),e08006

14. Yu Jin, Yang Sun, Shujie Zhao, Shuo Wang, John E. Tavis*, Zhuanchang Wu*, Peng Zhan*, Xinyong Liu*, Design, Synthesis, and Biological Evaluation of Highly Potent Boronic Acid (Boronate Ester)-Bearing Heteroaryl dihydropyrimidine Derivatives as HBV Capsid Assembly Modulators. Journal of Medicinal Chemistry, 2025;68(24),25939-25960

15. Xiangkai Ji, Xiangyi Jiang, Heng Gao, Zhen Gao, Erik De Clercq, Christophe Pannecouque*, Dongwei Kang*, Peng Zhan*, Xinyong Liu*. Structure- and Privileged Fragment-Based Iterative Optimization: Discovery of 2,4-Disubstituted-6-aminopyrimidines as Novel HIV-1 NNRTIs with Potent Activity against Drug-Resistant Strains and Favorable Safety Profiles. Journal of Medicinal Chemistry, 2025;68(21),23345-23362... 69

16. Xiangkai Ji, Xiangyi Jiang, Fabao Zhao, Erik De Clercq, Zhao Wang*, Christophe Pannecouque*, Dongwei Kang*, Peng Zhan*, Xinyong Liu*. Exploring the HIV-1 Reverse Transcriptase p51/p66 Interface: Structure-Based Design and Optimization of Novel 2,4,6-Trisubstituted Pyrimidines as Potent NNRTIs with Improved Resistance Profiles. Journal of Medicinal Chemistry 2025;68(19),20519-20535

17. Tao Zhang, Yue Yang, Xin Li, Fabao Zhao, Zongji Zhuo, Le Wang, Wenbo Zhang, Erik De Clercq, Christophe Pannecouque*, Peng Zhan*, Dongwei Kang*, Xinyong Liu*. Probing the Dominant Motifs within the Hydrophobic Channel Yields Oxadiazole-Containing Diarylpyrimidine Derivatives as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors. Journal of Medicinal Chemistry, 2025;68(15),16197-16211

18. Shuo Wang, Feiyue Ma, Craig W Lindsley*, Shujing Xu*, Xinyong Liu*, Peng Zhan*. Recent Advances in Long-Acting Antiviral Agents: Innovations in Design and Strategies for Extended Duration. Journal of Medicinal Chemistry, 2026;69(1):10-29

19. ZhenzhenZhou, Weifeng Zhang, Fabao Zhao, Ni Gao, Sining Tao, Na Wang, Jing-Jing Jiang*, Fan Yang*, Jin-Peng Sun*, Xinyong Liu*, Dongwei Kang*. In Silico Discovery of Novel Potent Trace Amine-Associated Receptor TAAR1 Agonists as Promising Drug Candidates for the Treatment of Schizophrenia. Journal of Medicinal Chemistry, 2025;68(10), 10255-10267

20. Minghui Liang, Yutong Dou, Jian Zhang, Zechun Yang, Lei Zhang, Zhuanchang Wu*, Xinyong Liu*, Peng Zhan*, Haiyong Jia*. Multisite Occupancy and Multidimensional Optimization: Design and Evaluation of Piperazine-Thioureidobenzamide Derivatives as Potent HBV Capsid Assembly Modulators. Journal of Medicinal Chemistry, 2025;68(22),24358-24380